Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Disclaimer
Right arrow Request Permissions
Google Scholar
Right arrow Articles by McGovern, M.
Right arrow Search for Related Content
PubMed
Right arrow Articles by McGovern, M.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The European Society of Cardiology 2005. All rights reserved. For Permissions, please e-mail: journals.permissions@oupjournals.org

Niaspan®: creating a new concept for raising HDL-cholesterol

Mark McGovern*

Kos Pharmaceuticals Inc., Miami, FL, USA

* Corresponding author: 2200 North Commerce Parkway, Suite 300 Weston, FL 33326-3258, USA. Tel: +1 954 331 3730; fax: +1 954 331 3892. E-mail address: mmcgovern{at}kospharm.com

Low high-density lipoprotein (HDL)-cholesterol is associated with increased cardiovascular risk and often persists despite treatment with a statin. Nicotinic acid is the most effective agent available for correcting low HDL-cholesterol, but tolerability concerns have limited its use in the past. Niaspan® is a new, once-daily, prolonged-release formulation of nicotinic acid, which provides equivalent efficacy on the lipid profile to the immediate-release formulation. Treatment with Niaspan, alone or combined with a statin, is associated with marked improvements on HDL-cholesterol. Useful additional reductions in triglycerides and low density lipoprotein-cholesterol also occur when Niaspan is added to statin therapy. Analysis of lipid subprofiles shows that Niaspan treatment induces a shift from small, dense, highly atherogenic lipoproteins to a less atherogenic lipid profile, which is characterized by larger, more buoyant lipoprotein particles. The tolerability profile of Niaspan is superior to that of immediate-release nicotinic acid, with a significantly reduced frequency of flushing, and an incidence of hepatotoxicity or muscle side-effects similar to that of a statin. This beneficial therapeutic profile is also observed among patients with type 2 diabetes or the metabolic syndrome, with minimal impact on glycaemic control. Niaspan provides a practical new approach to the correction of low HDL-cholesterol in everyday clinical practice.

Key Words: Nicotinic acid • Cholesterol • Lipid profiles • Cardiovascular risk • HMG-CoA reductase inhibitors • Dyslipidaemia • Niaspan®


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Eur Heart JHome page
M. J. Chapman, W. Le Goff, M. Guerin, and A. Kontush
Cholesteryl ester transfer protein: at the heart of the action of lipid-modulating therapy with statins, fibrates, niacin, and cholesteryl ester transfer protein inhibitors
Eur. Heart J., January 2, 2010; 31(2): 149 - 164.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.